Report overview
Clostridium difficile infection (CDI or C-dif) is a symptomatic infection due to the spore-forming bacterium, Clostridium difficile.[2] Symptoms include watery diarrhea, fever, nausea, and abdominal pain. It makes up about 20% of cases of antibiotic-associated diarrhea. Complications may include pseudomembranous colitis, toxic megacolon, perforation of the colon, and sepsis.
This report contains market size and forecasts of Molecular Clostridium Difficile Diagnostic Equipment in global, including the following market information:
Global Molecular Clostridium Difficile Diagnostic Equipment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Molecular Clostridium Difficile Diagnostic Equipment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Molecular Clostridium Difficile Diagnostic Equipment companies in 2021 (%)
The global Molecular Clostridium Difficile Diagnostic Equipment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Portable Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Molecular Clostridium Difficile Diagnostic Equipment include Roche, Thermo Fisher Scientific, Merck, Pfizer, Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics and Baxter International, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Molecular Clostridium Difficile Diagnostic Equipment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Molecular Clostridium Difficile Diagnostic Equipment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Clostridium Difficile Diagnostic Equipment Market Segment Percentages, by Type, 2021 (%)
Portable
Desktop
Global Molecular Clostridium Difficile Diagnostic Equipment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Clostridium Difficile Diagnostic Equipment Market Segment Percentages, by Application, 2021 (%)
Hospitals & Clinics
Diagnostic Laboratories
Others
Global Molecular Clostridium Difficile Diagnostic Equipment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Molecular Clostridium Difficile Diagnostic Equipment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Molecular Clostridium Difficile Diagnostic Equipment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Molecular Clostridium Difficile Diagnostic Equipment revenues share in global market, 2021 (%)
Key companies Molecular Clostridium Difficile Diagnostic Equipment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Molecular Clostridium Difficile Diagnostic Equipment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Thermo Fisher Scientific
Merck
Pfizer
Actelion Pharmaceuticals
Abbott Laboratories
Trinity Biotech
Summit Therapeutics
Baxter International
Sanofi
Novartis
AstraZeneca
